These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8654638)

  • 1. Endometrial response to hormone replacement therapy as assessed by expression of insulin-like growth factor-binding protein-1 in the endometrium.
    Suhonen S; Haukkamaa M; Holmström T; Lähteenmäki P; Rutanen EM
    Fertil Steril; 1996 Apr; 65(4):776-82. PubMed ID: 8654638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A; Rutanen EM
    Maturitas; 1995 Nov; 22(3):255-62. PubMed ID: 8746884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery.
    Rutanen EM
    Hum Reprod; 2000 Aug; 15 Suppl 3():173-81. PubMed ID: 11041233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium.
    Salmi A; Pakarinen P; Peltola AM; Rutanen EM
    Mol Hum Reprod; 1998 Dec; 4(12):1110-5. PubMed ID: 9872360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium.
    Pekonen F; Nyman T; Lähteenmäki P; Haukkamaa M; Rutanen EM
    J Clin Endocrinol Metab; 1992 Aug; 75(2):660-4. PubMed ID: 1379263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.
    Raudaskoski T; Tapanainen J; Tomás E; Luotola H; Pekonen F; Ronni-Sivula H; Timonen H; Riphagen F; Laatikainen T
    BJOG; 2002 Feb; 109(2):136-44. PubMed ID: 11888095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system.
    Rutanen EM; Salmi A; Nyman T
    Mol Hum Reprod; 1997 Sep; 3(9):749-54. PubMed ID: 9357999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen.
    Philip S; Taylor AH; Konje JC; Habiba M
    J Obstet Gynaecol; 2019 Nov; 39(8):1117-1122. PubMed ID: 31195902
    [TBL]